Pharming announces commitment to build a new downstream manufacturing facility for RUCONEST®

''With an increasing demand for RUCONEST® for the treatment of hereditary angioedema and an increasing need for rhC1INH in our clinical trials in new, large indications, we continue to invest in expanding our in-house processing capabilities'' — Sijmen de Vries - CEO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗